TRI.TO -0.02C -1.89GFL.TO 2.01BRK.B -4.78PLUS -0.79TGTX 1.01LLY -33.23SU.TO 2.79
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
DON'T BUY

Pfizer Inc(PFE)

Jul 13, 2005
Growth rate went from 30% three years ago to almost low single digits or flat. Not performing well. The group is in the early stages of a turn around, but would be more inclined to buy the company that has flourished through this period. Would prefer Abbott Labs (ABT-N).
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$27.23

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 06, 2005
The whole area has been beaten up and is very interesting. The big pharmas have a big challenge as the pipelines are a little bit bare. Would rather own companies that are suppliers to the pharmas, such as IMS Health (RX-N). (He doesn't follow big caps.)
Photo of Phil TallerPhil Taller
No
Unlock Rating
$26.77

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 02, 2005
RE:Call options Jan/07. Not particularily expensive as it has not been a volatile stock. Not a bad way to play the stock if you are bullish on the company. The company has a very good dividend, so call option are less than the put options quite often. (His play on this is through the Vipers (VHT-A).)
Photo of Richard CroftRichard Croft
No
Unlock Rating
$27.50

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 25, 2005
Got in on the Celebrex recall. This company has developed some fantastic drugs. Pharmaceutical stocks in the US have been absolutely decimated. Dirt cheap. 3.5% didvidend yield while you wait for a recovery. Generates a ton of free cash flow. Merck & Company (MRK-N) are in the same way.
Photo of David Taylor, MBA, CFADavid Taylor, MBA, CFA
Owned
Unlock Rating
$27.03

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 11, 2005
This company, along with the other drug stocks, has had a very big problem. Fell below its 200 day moving average. There is no base.
Photo of Ron MeiselsRon Meisels
No
Unlock Rating
$26.46

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 28, 2005
(A Top Pick Jan24/05. Up 8%.) Still likes.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$26.23

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Mar 21, 2005
Pharmaceuticals have pretty good cash flows, but their stocks are going nowhere. Cheap on a relative basis to where they've been. Have one big overhang as a group, i.e., there are a lot of patent expiries that are going to happen in 2006. May not be a bad time to start picking them up.
Photo of Martin Hubbes, CFAMartin Hubbes, CFA
Owned
Unlock Rating
$25.71

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 15, 2005
A good long term hold. Historically cheap.
Photo of George LougheryGeorge Loughery
Owned
Unlock Rating
$26.29

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 25, 2005
Likes the pharmaceutical industry. The market is not thinking about the tremendous amount of cash they throw off and that they are cheap. Made the right move by not taking Celebrex off the market. Good pipeline.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$26.86

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 22, 2005
In their top 10. Great valuation.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.59

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 18, 2005
FDA has given the OK on the controversial drugs. Pfizer is a very strong company and has the best pipeline of all the large drug companies. Continues to generate billions of $'s of free cash flow. YOu won't get rich, but you'll make some money.
Photo of Andrew McCreathAndrew McCreath
Owned
Unlock Rating
$26.80

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 09, 2005
Over a 3/5 year period, it's probably OK, but it's trending down and there's no reason to get in the way of that until it changes direction. There is pricing pressure in the drug industry, product liability questions, cross border shopping , etc.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$25.05

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 07, 2005
Likes this one a lot. Trading at 11 X earnings and a 3% dividend yield and waiting to see if Cellebrex gets FDA OK. Downside is pretty limited.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$24.91

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 07, 2005
Big headline risk and he loves stock with headline risks. Trading at a 50% discount to what it's really worth.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$24.91

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 07, 2005
There is no technical sign that the ugliness has changed yet. No real strong support for the stock here. However, long term pharma sector is an interesting play.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$24.91

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Showing 676 to 690 of 894 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AMZN -2.38$248
META -6.23$642.62
VRT -1.27$194.32
WFC -0.62$82.39
ZS 17.39$255.15
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

TRI.TO -0.02$172.41
C -1.89$120.62
GFL.TO 2.01$63.75
BRK.B -4.78$542.19
PLUS -0.79$95.36

Popular Articles

Latest Sell Signals

DOV 0$
BA 0.8$188.35
AC.TO -1.03$21.11
BB.TO 0.44$12.46
TSM 6.16$418.51

Most Recent Experts

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Tim Regan

Tim Regan

Kingwest & Company

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like